Table 1. Open in new tab Patient...

	Overall (n = 78)	Survivor (n = 42)	Non-survivor (n = 36)	P-value
Sex
Female (%)	22 (28.2)	12 (28.6)	10 (27.8)	1
Male (%)	56 (71.8)	30 (71.4)	26 (72.2)
Age (years)
n	78	42	36	0.741
Median (Q1, Q3)	59.0 (50.3, 68.8)	57.0 (50.3, 68.0)	61.5 (49.8, 71.3)
Ethnicity
Black/African/Caribbean (%)	13 (16.7)	7 (16.7)	6 (16.7)	0.445
Mixed/multiple ethnic groups (%)	8 (10.3)	4 (9.5)	4 (11.1)
White (%)	51 (65.4)	29 (69.0)	22 (61.1)
Asian (%)	1 (1.3)	0 (0)	1 (2.8)
Other ethnic group (%)	2 (2.6)	0 (0)	2 (5.6)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
Weight (kg)
n	75	42	33	0.847
Median (Q1, Q3)	90.0 (79.0, 100)	90.0 (79.0, 109)	90.0 (80.0, 96.0)
Missing (%)	3 (3.8)	0 (0)	3 (8.3)
Height (cm)
n	72	39	33	0.995
Median (Q1, Q3)	173 (168, 178)	174 (168, 178)	173 (168, 177)
Missing (%)	6 (7.7)	3 (7.1)	3 (8.3)
ICU admission
No (%)	9 (11.5)	8 (19.0)	1 (2.8)	0.0592
Yes (%)	69 (88.5)	34 (81.0)	35 (97.2)
SOFA score
n	71	39	32	0.194
Median (Q1, Q3)	9.00 (7.00, 12.5)	9.00 (7.00, 12.0)	11.0 (8.00, 13.3)
Missing (%)	7 (9.0)	3 (7.1)	4 (11.1)
4C score
n	47	29	18	0.0157
Median (Q1, Q3)	12.0 (9.50, 14.0)	11.0 (8.00, 12.0)	12.5 (11.3, 14.0)
Missing (%)	31 (39.7)	13 (31.0)	18 (50.0)
Mechanical ventilation
No (%)	23 (29.5)	15 (35.7)	8 (22.2)	0.262
Yes (%)	52 (66.7)	25 (59.5)	27 (75.0)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
PaO₂/FiO₂
n	67	36	31	0.692
Median (Q1, Q3)	119 (71.5, 167)	120 (75.5, 170)	111 (67.2, 152)
Missing (%)	11 (14.1)	6 (14.3)	5 (13.9)
Vasopressors
No (%)	35 (44.9)	20 (47.6)	15 (41.7)	0.734
Yes (%)	32 (41.0)	16 (38.1)	16 (44.4)
Missing (%)	11 (14.1)	6 (14.3)	5 (13.9)
Bacterial superinfection
No (%)	47 (60.3)	30 (71.4)	17 (47.2)	0.0517
Yes (%)	31 (39.7)	12 (28.6)	19 (52.8)
KRT dependency
No (%)	54 (69.2)	29 (69.0)	25 (69.4)	1
Yes (%)	22 (28.2)	12 (28.6)	10 (27.8)
Missing (%)	2 (2.6)	1 (2.4)	1 (2.8)
ECMO
No (%)	74 (94.9)	41 (97.6)	33 (91.7)	0.501
Yes (%)	4 (5.1)	1 (2.4)	3 (8.3)
Intermittent haemodialysis
No (%)	54 (69.2)	28 (66.7)	26 (72.2)	0.776
Yes (%)	24 (30.8)	14 (33.3)	10 (27.8)
Seraph as standalone treatment
No (%)	39 (50.0)	18 (42.9)	21 (58.3)	0.287
Yes (%)	36 (46.2)	22 (52.4)	14 (38.9)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
CRP (mg/L)
n	73	40	33	0.907
Median (Q1, Q3)	155 (97.0, 279)	149 (110, 24)	162 (83.0, 386)
Missing (%)	5 (6.4)	2 (4.8)	3 (8.3)
PCT (µg/L)
n	72	37	35	0.0884
Median (Q1, Q3)	1.50 (0.400, 10.9)	0.600 (0.400, 6.00)	4.40 (0.650, 13.8)
Missing (%)	6 (7.7)	5 (11.9)	1 (2.8)
Leucocytes
n	76	41	35	0.26
Median (Q1, Q3)	11.0 (8.43, 14.8)	10.3 (7.30, 14.8)	11.9 (9.45, 14.9)
Missing (%)	2 (2.6)	1 (2.4)	1 (2.8)
Ferritin (ng/mL)
n	48	30	18	0.0418
Median (Q1, Q3)	1260 (894, 2880)	1010 (777, 2000)	1980 (1040, 8140)
Missing (%)	30 (38.5)	12 (28.6)	18 (50.0)
d-Dimer (mg/L)
n	66	38	28	0.364
Median (Q1, Q3)	3.53 (1.07, 25.1)	2.41 (0.848, 24.7)	4.18 (1.51, 23.3)
Missing (%)	12 (15.4)	4 (9.5)	8 (22.2)
Length of ICU stay (days)
n	69	34	35	0.299
Median (Q1, Q3)	17.0 (10.0, 27.0)	15.0 (7.50, 26.3)	19.0 (14.0, 25.5)
Missing (%)	9 (11.5)	8 (19.0)	1 (2.8)
Length of hospital stay (days)
n	78	42	36	0.173
Median (Q1, Q3)	22.0 (15.0, 33.3)	23.5 (16.3, 37.0)	20.0 (13.0, 30.3)
Time from symptoms to Seraph treatment (days)
n	74	39	35	0.0211
Median (Q1, Q3)	12.3 (7.43, 15.5)	9.56 (6.60, 14.6)	13.0 (11.0, 19.5)
Missing (%)	4 (5.1)	3 (7.1)	1 (2.8)
Time from ICU admission to Seraph treatment (days)
n	69	34	35	0.0023
Median (Q1, Q3)	2.55 (1.53, 6.00)	1.73 (1.50, 3.24)	4.58 (2.05, 11.4)
Missing (%)	9^a (11.5)	8 (19.0)	1 (2.8)

Overall (n = 78)

Survivor (n = 42)

Non-survivor (n = 36)

P-value

Sex

Female (%)

22 (28.2)

12 (28.6)

10 (27.8)

Male (%)

56 (71.8)

30 (71.4)

26 (72.2)

Age (years)

0.741

Median (Q1, Q3)

59.0 (50.3, 68.8)

57.0 (50.3, 68.0)

61.5 (49.8, 71.3)

Ethnicity

Black/African/Caribbean (%)

13 (16.7)

7 (16.7)

6 (16.7)

0.445

Mixed/multiple ethnic groups (%)

8 (10.3)

4 (9.5)

4 (11.1)

White (%)

51 (65.4)

29 (69.0)

22 (61.1)

Asian (%)

1 (1.3)

0 (0)

1 (2.8)

Other ethnic group (%)

2 (2.6)

0 (0)

2 (5.6)

Missing (%)

3 (3.8)

2 (4.8)

1 (2.8)

Weight (kg)

0.847

Median (Q1, Q3)

90.0 (79.0, 100)

90.0 (79.0, 109)

90.0 (80.0, 96.0)

Missing (%)

3 (3.8)

0 (0)

3 (8.3)

Height (cm)

0.995

Median (Q1, Q3)

173 (168, 178)

174 (168, 178)

173 (168, 177)

Missing (%)

6 (7.7)

3 (7.1)

3 (8.3)

ICU admission

No (%)

9 (11.5)

8 (19.0)

1 (2.8)

0.0592

Yes (%)

69 (88.5)

34 (81.0)

35 (97.2)

SOFA score

0.194

Median (Q1, Q3)

9.00 (7.00, 12.5)

9.00 (7.00, 12.0)

11.0 (8.00, 13.3)

Missing (%)

7 (9.0)

3 (7.1)

4 (11.1)

4C score

0.0157

Median (Q1, Q3)

12.0 (9.50, 14.0)

11.0 (8.00, 12.0)

12.5 (11.3, 14.0)

Missing (%)

31 (39.7)

13 (31.0)

18 (50.0)

Mechanical ventilation

No (%)

23 (29.5)

15 (35.7)

8 (22.2)

0.262

Yes (%)

52 (66.7)

25 (59.5)

27 (75.0)

Missing (%)

3 (3.8)

2 (4.8)

1 (2.8)

PaO₂/FiO₂

0.692

Median (Q1, Q3)

119 (71.5, 167)

120 (75.5, 170)

111 (67.2, 152)

Missing (%)

11 (14.1)

6 (14.3)

5 (13.9)

Vasopressors

No (%)

35 (44.9)

20 (47.6)

15 (41.7)

0.734

Yes (%)

32 (41.0)

16 (38.1)

16 (44.4)

Missing (%)

11 (14.1)

6 (14.3)

5 (13.9)

Bacterial superinfection

No (%)

47 (60.3)

30 (71.4)

17 (47.2)

0.0517

Yes (%)

31 (39.7)

12 (28.6)

19 (52.8)

KRT dependency

No (%)

54 (69.2)

29 (69.0)

25 (69.4)

Yes (%)

22 (28.2)

12 (28.6)

10 (27.8)

Missing (%)

2 (2.6)

1 (2.4)

1 (2.8)

ECMO

No (%)

74 (94.9)

41 (97.6)

33 (91.7)

0.501

Yes (%)

4 (5.1)

1 (2.4)

3 (8.3)

Intermittent haemodialysis

No (%)

54 (69.2)

28 (66.7)

26 (72.2)

0.776

Yes (%)

24 (30.8)

14 (33.3)

10 (27.8)

Seraph as standalone treatment

No (%)

39 (50.0)

18 (42.9)

21 (58.3)

0.287

Yes (%)

36 (46.2)

22 (52.4)

14 (38.9)

Missing (%)

3 (3.8)

2 (4.8)

1 (2.8)

CRP (mg/L)

0.907

Median (Q1, Q3)

155 (97.0, 279)

149 (110, 24)

162 (83.0, 386)

Missing (%)

5 (6.4)

2 (4.8)

3 (8.3)

PCT (µg/L)

0.0884

Median (Q1, Q3)

1.50 (0.400, 10.9)

0.600 (0.400, 6.00)

4.40 (0.650, 13.8)

Missing (%)

6 (7.7)

5 (11.9)

1 (2.8)

Leucocytes

0.26

Median (Q1, Q3)

11.0 (8.43, 14.8)

10.3 (7.30, 14.8)

11.9 (9.45, 14.9)

Missing (%)

2 (2.6)

1 (2.4)

1 (2.8)

Ferritin (ng/mL)

0.0418

Median (Q1, Q3)

1260 (894, 2880)

1010 (777, 2000)

1980 (1040, 8140)

Missing (%)

30 (38.5)

12 (28.6)

18 (50.0)

d-Dimer (mg/L)

0.364

Median (Q1, Q3)

3.53 (1.07, 25.1)

2.41 (0.848, 24.7)

4.18 (1.51, 23.3)

Missing (%)

12 (15.4)

4 (9.5)

8 (22.2)

Length of ICU stay (days)

0.299

Median (Q1, Q3)

17.0 (10.0, 27.0)

15.0 (7.50, 26.3)

19.0 (14.0, 25.5)

Missing (%)

9 (11.5)

8 (19.0)

1 (2.8)

Length of hospital stay (days)

0.173

Median (Q1, Q3)

22.0 (15.0, 33.3)

23.5 (16.3, 37.0)

20.0 (13.0, 30.3)

Time from symptoms to Seraph treatment (days)

0.0211

Median (Q1, Q3)

12.3 (7.43, 15.5)

9.56 (6.60, 14.6)

13.0 (11.0, 19.5)

Missing (%)

4 (5.1)

3 (7.1)

1 (2.8)

Time from ICU admission to Seraph treatment (days)

0.0023

Median (Q1, Q3)

2.55 (1.53, 6.00)

1.73 (1.50, 3.24)

4.58 (2.05, 11.4)

Missing (%)

9^a (11.5)

8 (19.0)

1 (2.8)

	Overall (n = 78)	Survivor (n = 42)	Non-survivor (n = 36)	P-value
Sex
Female (%)	22 (28.2)	12 (28.6)	10 (27.8)	1
Male (%)	56 (71.8)	30 (71.4)	26 (72.2)
Age (years)
n	78	42	36	0.741
Median (Q1, Q3)	59.0 (50.3, 68.8)	57.0 (50.3, 68.0)	61.5 (49.8, 71.3)
Ethnicity
Black/African/Caribbean (%)	13 (16.7)	7 (16.7)	6 (16.7)	0.445
Mixed/multiple ethnic groups (%)	8 (10.3)	4 (9.5)	4 (11.1)
White (%)	51 (65.4)	29 (69.0)	22 (61.1)
Asian (%)	1 (1.3)	0 (0)	1 (2.8)
Other ethnic group (%)	2 (2.6)	0 (0)	2 (5.6)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
Weight (kg)
n	75	42	33	0.847
Median (Q1, Q3)	90.0 (79.0, 100)	90.0 (79.0, 109)	90.0 (80.0, 96.0)
Missing (%)	3 (3.8)	0 (0)	3 (8.3)
Height (cm)
n	72	39	33	0.995
Median (Q1, Q3)	173 (168, 178)	174 (168, 178)	173 (168, 177)
Missing (%)	6 (7.7)	3 (7.1)	3 (8.3)
ICU admission
No (%)	9 (11.5)	8 (19.0)	1 (2.8)	0.0592
Yes (%)	69 (88.5)	34 (81.0)	35 (97.2)
SOFA score
n	71	39	32	0.194
Median (Q1, Q3)	9.00 (7.00, 12.5)	9.00 (7.00, 12.0)	11.0 (8.00, 13.3)
Missing (%)	7 (9.0)	3 (7.1)	4 (11.1)
4C score
n	47	29	18	0.0157
Median (Q1, Q3)	12.0 (9.50, 14.0)	11.0 (8.00, 12.0)	12.5 (11.3, 14.0)
Missing (%)	31 (39.7)	13 (31.0)	18 (50.0)
Mechanical ventilation
No (%)	23 (29.5)	15 (35.7)	8 (22.2)	0.262
Yes (%)	52 (66.7)	25 (59.5)	27 (75.0)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
PaO₂/FiO₂
n	67	36	31	0.692
Median (Q1, Q3)	119 (71.5, 167)	120 (75.5, 170)	111 (67.2, 152)
Missing (%)	11 (14.1)	6 (14.3)	5 (13.9)
Vasopressors
No (%)	35 (44.9)	20 (47.6)	15 (41.7)	0.734
Yes (%)	32 (41.0)	16 (38.1)	16 (44.4)
Missing (%)	11 (14.1)	6 (14.3)	5 (13.9)
Bacterial superinfection
No (%)	47 (60.3)	30 (71.4)	17 (47.2)	0.0517
Yes (%)	31 (39.7)	12 (28.6)	19 (52.8)
KRT dependency
No (%)	54 (69.2)	29 (69.0)	25 (69.4)	1
Yes (%)	22 (28.2)	12 (28.6)	10 (27.8)
Missing (%)	2 (2.6)	1 (2.4)	1 (2.8)
ECMO
No (%)	74 (94.9)	41 (97.6)	33 (91.7)	0.501
Yes (%)	4 (5.1)	1 (2.4)	3 (8.3)
Intermittent haemodialysis
No (%)	54 (69.2)	28 (66.7)	26 (72.2)	0.776
Yes (%)	24 (30.8)	14 (33.3)	10 (27.8)
Seraph as standalone treatment
No (%)	39 (50.0)	18 (42.9)	21 (58.3)	0.287
Yes (%)	36 (46.2)	22 (52.4)	14 (38.9)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
CRP (mg/L)
n	73	40	33	0.907
Median (Q1, Q3)	155 (97.0, 279)	149 (110, 24)	162 (83.0, 386)
Missing (%)	5 (6.4)	2 (4.8)	3 (8.3)
PCT (µg/L)
n	72	37	35	0.0884
Median (Q1, Q3)	1.50 (0.400, 10.9)	0.600 (0.400, 6.00)	4.40 (0.650, 13.8)
Missing (%)	6 (7.7)	5 (11.9)	1 (2.8)
Leucocytes
n	76	41	35	0.26
Median (Q1, Q3)	11.0 (8.43, 14.8)	10.3 (7.30, 14.8)	11.9 (9.45, 14.9)
Missing (%)	2 (2.6)	1 (2.4)	1 (2.8)
Ferritin (ng/mL)
n	48	30	18	0.0418
Median (Q1, Q3)	1260 (894, 2880)	1010 (777, 2000)	1980 (1040, 8140)
Missing (%)	30 (38.5)	12 (28.6)	18 (50.0)
d-Dimer (mg/L)
n	66	38	28	0.364
Median (Q1, Q3)	3.53 (1.07, 25.1)	2.41 (0.848, 24.7)	4.18 (1.51, 23.3)
Missing (%)	12 (15.4)	4 (9.5)	8 (22.2)
Length of ICU stay (days)
n	69	34	35	0.299
Median (Q1, Q3)	17.0 (10.0, 27.0)	15.0 (7.50, 26.3)	19.0 (14.0, 25.5)
Missing (%)	9 (11.5)	8 (19.0)	1 (2.8)
Length of hospital stay (days)
n	78	42	36	0.173
Median (Q1, Q3)	22.0 (15.0, 33.3)	23.5 (16.3, 37.0)	20.0 (13.0, 30.3)
Time from symptoms to Seraph treatment (days)
n	74	39	35	0.0211
Median (Q1, Q3)	12.3 (7.43, 15.5)	9.56 (6.60, 14.6)	13.0 (11.0, 19.5)
Missing (%)	4 (5.1)	3 (7.1)	1 (2.8)
Time from ICU admission to Seraph treatment (days)
n	69	34	35	0.0023
Median (Q1, Q3)	2.55 (1.53, 6.00)	1.73 (1.50, 3.24)	4.58 (2.05, 11.4)
Missing (%)	9^a (11.5)	8 (19.0)	1 (2.8)

Overall (n = 78)

Survivor (n = 42)

Non-survivor (n = 36)

P-value

Sex

Female (%)

22 (28.2)

12 (28.6)

10 (27.8)

Male (%)

56 (71.8)

30 (71.4)

26 (72.2)

Age (years)

0.741

Median (Q1, Q3)

59.0 (50.3, 68.8)

57.0 (50.3, 68.0)

61.5 (49.8, 71.3)

Ethnicity

Black/African/Caribbean (%)

13 (16.7)

7 (16.7)

6 (16.7)

0.445

Mixed/multiple ethnic groups (%)

8 (10.3)

4 (9.5)

4 (11.1)

White (%)

51 (65.4)

29 (69.0)

22 (61.1)

Asian (%)

1 (1.3)

0 (0)

1 (2.8)

Other ethnic group (%)

2 (2.6)

0 (0)

2 (5.6)

Missing (%)

3 (3.8)

2 (4.8)

1 (2.8)

Weight (kg)

0.847

Median (Q1, Q3)

90.0 (79.0, 100)

90.0 (79.0, 109)

90.0 (80.0, 96.0)

Missing (%)

3 (3.8)

0 (0)

3 (8.3)

Height (cm)

0.995

Median (Q1, Q3)

173 (168, 178)

174 (168, 178)

173 (168, 177)

Missing (%)

6 (7.7)

3 (7.1)

3 (8.3)

ICU admission

No (%)

9 (11.5)

8 (19.0)

1 (2.8)

0.0592

Yes (%)

69 (88.5)

34 (81.0)

35 (97.2)

SOFA score

0.194

Median (Q1, Q3)

9.00 (7.00, 12.5)

9.00 (7.00, 12.0)

11.0 (8.00, 13.3)

Missing (%)

7 (9.0)

3 (7.1)

4 (11.1)

4C score

0.0157

Median (Q1, Q3)

12.0 (9.50, 14.0)

11.0 (8.00, 12.0)

12.5 (11.3, 14.0)

Missing (%)

31 (39.7)

13 (31.0)

18 (50.0)

Mechanical ventilation

No (%)

23 (29.5)

15 (35.7)

8 (22.2)

0.262

Yes (%)

52 (66.7)

25 (59.5)

27 (75.0)

Missing (%)

3 (3.8)

2 (4.8)

1 (2.8)

PaO₂/FiO₂

0.692

Median (Q1, Q3)

119 (71.5, 167)

120 (75.5, 170)

111 (67.2, 152)

Missing (%)

11 (14.1)

6 (14.3)

5 (13.9)

Vasopressors

No (%)

35 (44.9)

20 (47.6)

15 (41.7)

0.734

Yes (%)

32 (41.0)

16 (38.1)

16 (44.4)

Missing (%)

11 (14.1)

6 (14.3)

5 (13.9)

Bacterial superinfection

No (%)

47 (60.3)

30 (71.4)

17 (47.2)

0.0517

Yes (%)

31 (39.7)

12 (28.6)

19 (52.8)

KRT dependency

No (%)

54 (69.2)

29 (69.0)

25 (69.4)

Yes (%)

22 (28.2)

12 (28.6)

10 (27.8)

Missing (%)

2 (2.6)

1 (2.4)

1 (2.8)

ECMO

No (%)

74 (94.9)

41 (97.6)

33 (91.7)

0.501

Yes (%)

4 (5.1)

1 (2.4)

3 (8.3)

Intermittent haemodialysis

No (%)

54 (69.2)

28 (66.7)

26 (72.2)

0.776

Yes (%)

24 (30.8)

14 (33.3)

10 (27.8)

Seraph as standalone treatment

No (%)

39 (50.0)

18 (42.9)

21 (58.3)

0.287

Yes (%)

36 (46.2)

22 (52.4)

14 (38.9)

Missing (%)

3 (3.8)

2 (4.8)

1 (2.8)

CRP (mg/L)

0.907

Median (Q1, Q3)

155 (97.0, 279)

149 (110, 24)

162 (83.0, 386)

Missing (%)

5 (6.4)

2 (4.8)

3 (8.3)

PCT (µg/L)

0.0884

Median (Q1, Q3)

1.50 (0.400, 10.9)

0.600 (0.400, 6.00)

4.40 (0.650, 13.8)

Missing (%)

6 (7.7)

5 (11.9)

1 (2.8)

Leucocytes

0.26

Median (Q1, Q3)

11.0 (8.43, 14.8)

10.3 (7.30, 14.8)

11.9 (9.45, 14.9)

Missing (%)

2 (2.6)

1 (2.4)

1 (2.8)

Ferritin (ng/mL)

0.0418

Median (Q1, Q3)

1260 (894, 2880)

1010 (777, 2000)

1980 (1040, 8140)

Missing (%)

30 (38.5)

12 (28.6)

18 (50.0)

d-Dimer (mg/L)

0.364

Median (Q1, Q3)

3.53 (1.07, 25.1)

2.41 (0.848, 24.7)

4.18 (1.51, 23.3)

Missing (%)

12 (15.4)

4 (9.5)

8 (22.2)

Length of ICU stay (days)

0.299

Median (Q1, Q3)

17.0 (10.0, 27.0)

15.0 (7.50, 26.3)

19.0 (14.0, 25.5)

Missing (%)

9 (11.5)

8 (19.0)

1 (2.8)

Length of hospital stay (days)

0.173

Median (Q1, Q3)

22.0 (15.0, 33.3)

23.5 (16.3, 37.0)

20.0 (13.0, 30.3)

Time from symptoms to Seraph treatment (days)

0.0211

Median (Q1, Q3)

12.3 (7.43, 15.5)

9.56 (6.60, 14.6)

13.0 (11.0, 19.5)

Missing (%)

4 (5.1)

3 (7.1)

1 (2.8)

Time from ICU admission to Seraph treatment (days)

0.0023

Median (Q1, Q3)

2.55 (1.53, 6.00)

1.73 (1.50, 3.24)

4.58 (2.05, 11.4)

Missing (%)

9^a (11.5)

8 (19.0)

1 (2.8)

Table 1.

Open in new tab

Patient characteristics of the entire cohort as well as for survivors and non-survivors, and significance level of the difference between survivors and non-survivors

	Overall (n = 78)	Survivor (n = 42)	Non-survivor (n = 36)	P-value
Sex
Female (%)	22 (28.2)	12 (28.6)	10 (27.8)	1
Male (%)	56 (71.8)	30 (71.4)	26 (72.2)
Age (years)
n	78	42	36	0.741
Median (Q1, Q3)	59.0 (50.3, 68.8)	57.0 (50.3, 68.0)	61.5 (49.8, 71.3)
Ethnicity
Black/African/Caribbean (%)	13 (16.7)	7 (16.7)	6 (16.7)	0.445
Mixed/multiple ethnic groups (%)	8 (10.3)	4 (9.5)	4 (11.1)
White (%)	51 (65.4)	29 (69.0)	22 (61.1)
Asian (%)	1 (1.3)	0 (0)	1 (2.8)
Other ethnic group (%)	2 (2.6)	0 (0)	2 (5.6)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
Weight (kg)
n	75	42	33	0.847
Median (Q1, Q3)	90.0 (79.0, 100)	90.0 (79.0, 109)	90.0 (80.0, 96.0)
Missing (%)	3 (3.8)	0 (0)	3 (8.3)
Height (cm)
n	72	39	33	0.995
Median (Q1, Q3)	173 (168, 178)	174 (168, 178)	173 (168, 177)
Missing (%)	6 (7.7)	3 (7.1)	3 (8.3)
ICU admission
No (%)	9 (11.5)	8 (19.0)	1 (2.8)	0.0592
Yes (%)	69 (88.5)	34 (81.0)	35 (97.2)
SOFA score
n	71	39	32	0.194
Median (Q1, Q3)	9.00 (7.00, 12.5)	9.00 (7.00, 12.0)	11.0 (8.00, 13.3)
Missing (%)	7 (9.0)	3 (7.1)	4 (11.1)
4C score
n	47	29	18	0.0157
Median (Q1, Q3)	12.0 (9.50, 14.0)	11.0 (8.00, 12.0)	12.5 (11.3, 14.0)
Missing (%)	31 (39.7)	13 (31.0)	18 (50.0)
Mechanical ventilation
No (%)	23 (29.5)	15 (35.7)	8 (22.2)	0.262
Yes (%)	52 (66.7)	25 (59.5)	27 (75.0)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
PaO₂/FiO₂
n	67	36	31	0.692
Median (Q1, Q3)	119 (71.5, 167)	120 (75.5, 170)	111 (67.2, 152)
Missing (%)	11 (14.1)	6 (14.3)	5 (13.9)
Vasopressors
No (%)	35 (44.9)	20 (47.6)	15 (41.7)	0.734
Yes (%)	32 (41.0)	16 (38.1)	16 (44.4)
Missing (%)	11 (14.1)	6 (14.3)	5 (13.9)
Bacterial superinfection
No (%)	47 (60.3)	30 (71.4)	17 (47.2)	0.0517
Yes (%)	31 (39.7)	12 (28.6)	19 (52.8)
KRT dependency
No (%)	54 (69.2)	29 (69.0)	25 (69.4)	1
Yes (%)	22 (28.2)	12 (28.6)	10 (27.8)
Missing (%)	2 (2.6)	1 (2.4)	1 (2.8)
ECMO
No (%)	74 (94.9)	41 (97.6)	33 (91.7)	0.501
Yes (%)	4 (5.1)	1 (2.4)	3 (8.3)
Intermittent haemodialysis
No (%)	54 (69.2)	28 (66.7)	26 (72.2)	0.776
Yes (%)	24 (30.8)	14 (33.3)	10 (27.8)
Seraph as standalone treatment
No (%)	39 (50.0)	18 (42.9)	21 (58.3)	0.287
Yes (%)	36 (46.2)	22 (52.4)	14 (38.9)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
CRP (mg/L)
n	73	40	33	0.907
Median (Q1, Q3)	155 (97.0, 279)	149 (110, 24)	162 (83.0, 386)
Missing (%)	5 (6.4)	2 (4.8)	3 (8.3)
PCT (µg/L)
n	72	37	35	0.0884
Median (Q1, Q3)	1.50 (0.400, 10.9)	0.600 (0.400, 6.00)	4.40 (0.650, 13.8)
Missing (%)	6 (7.7)	5 (11.9)	1 (2.8)
Leucocytes
n	76	41	35	0.26
Median (Q1, Q3)	11.0 (8.43, 14.8)	10.3 (7.30, 14.8)	11.9 (9.45, 14.9)
Missing (%)	2 (2.6)	1 (2.4)	1 (2.8)
Ferritin (ng/mL)
n	48	30	18	0.0418
Median (Q1, Q3)	1260 (894, 2880)	1010 (777, 2000)	1980 (1040, 8140)
Missing (%)	30 (38.5)	12 (28.6)	18 (50.0)
d-Dimer (mg/L)
n	66	38	28	0.364
Median (Q1, Q3)	3.53 (1.07, 25.1)	2.41 (0.848, 24.7)	4.18 (1.51, 23.3)
Missing (%)	12 (15.4)	4 (9.5)	8 (22.2)
Length of ICU stay (days)
n	69	34	35	0.299
Median (Q1, Q3)	17.0 (10.0, 27.0)	15.0 (7.50, 26.3)	19.0 (14.0, 25.5)
Missing (%)	9 (11.5)	8 (19.0)	1 (2.8)
Length of hospital stay (days)
n	78	42	36	0.173
Median (Q1, Q3)	22.0 (15.0, 33.3)	23.5 (16.3, 37.0)	20.0 (13.0, 30.3)
Time from symptoms to Seraph treatment (days)
n	74	39	35	0.0211
Median (Q1, Q3)	12.3 (7.43, 15.5)	9.56 (6.60, 14.6)	13.0 (11.0, 19.5)
Missing (%)	4 (5.1)	3 (7.1)	1 (2.8)
Time from ICU admission to Seraph treatment (days)
n	69	34	35	0.0023
Median (Q1, Q3)	2.55 (1.53, 6.00)	1.73 (1.50, 3.24)	4.58 (2.05, 11.4)
Missing (%)	9^a (11.5)	8 (19.0)	1 (2.8)

	Overall (n = 78)	Survivor (n = 42)	Non-survivor (n = 36)	P-value
Sex
Female (%)	22 (28.2)	12 (28.6)	10 (27.8)	1
Male (%)	56 (71.8)	30 (71.4)	26 (72.2)
Age (years)
n	78	42	36	0.741
Median (Q1, Q3)	59.0 (50.3, 68.8)	57.0 (50.3, 68.0)	61.5 (49.8, 71.3)
Ethnicity
Black/African/Caribbean (%)	13 (16.7)	7 (16.7)	6 (16.7)	0.445
Mixed/multiple ethnic groups (%)	8 (10.3)	4 (9.5)	4 (11.1)
White (%)	51 (65.4)	29 (69.0)	22 (61.1)
Asian (%)	1 (1.3)	0 (0)	1 (2.8)
Other ethnic group (%)	2 (2.6)	0 (0)	2 (5.6)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
Weight (kg)
n	75	42	33	0.847
Median (Q1, Q3)	90.0 (79.0, 100)	90.0 (79.0, 109)	90.0 (80.0, 96.0)
Missing (%)	3 (3.8)	0 (0)	3 (8.3)
Height (cm)
n	72	39	33	0.995
Median (Q1, Q3)	173 (168, 178)	174 (168, 178)	173 (168, 177)
Missing (%)	6 (7.7)	3 (7.1)	3 (8.3)
ICU admission
No (%)	9 (11.5)	8 (19.0)	1 (2.8)	0.0592
Yes (%)	69 (88.5)	34 (81.0)	35 (97.2)
SOFA score
n	71	39	32	0.194
Median (Q1, Q3)	9.00 (7.00, 12.5)	9.00 (7.00, 12.0)	11.0 (8.00, 13.3)
Missing (%)	7 (9.0)	3 (7.1)	4 (11.1)
4C score
n	47	29	18	0.0157
Median (Q1, Q3)	12.0 (9.50, 14.0)	11.0 (8.00, 12.0)	12.5 (11.3, 14.0)
Missing (%)	31 (39.7)	13 (31.0)	18 (50.0)
Mechanical ventilation
No (%)	23 (29.5)	15 (35.7)	8 (22.2)	0.262
Yes (%)	52 (66.7)	25 (59.5)	27 (75.0)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
PaO₂/FiO₂
n	67	36	31	0.692
Median (Q1, Q3)	119 (71.5, 167)	120 (75.5, 170)	111 (67.2, 152)
Missing (%)	11 (14.1)	6 (14.3)	5 (13.9)
Vasopressors
No (%)	35 (44.9)	20 (47.6)	15 (41.7)	0.734
Yes (%)	32 (41.0)	16 (38.1)	16 (44.4)
Missing (%)	11 (14.1)	6 (14.3)	5 (13.9)
Bacterial superinfection
No (%)	47 (60.3)	30 (71.4)	17 (47.2)	0.0517
Yes (%)	31 (39.7)	12 (28.6)	19 (52.8)
KRT dependency
No (%)	54 (69.2)	29 (69.0)	25 (69.4)	1
Yes (%)	22 (28.2)	12 (28.6)	10 (27.8)
Missing (%)	2 (2.6)	1 (2.4)	1 (2.8)
ECMO
No (%)	74 (94.9)	41 (97.6)	33 (91.7)	0.501
Yes (%)	4 (5.1)	1 (2.4)	3 (8.3)
Intermittent haemodialysis
No (%)	54 (69.2)	28 (66.7)	26 (72.2)	0.776
Yes (%)	24 (30.8)	14 (33.3)	10 (27.8)
Seraph as standalone treatment
No (%)	39 (50.0)	18 (42.9)	21 (58.3)	0.287
Yes (%)	36 (46.2)	22 (52.4)	14 (38.9)
Missing (%)	3 (3.8)	2 (4.8)	1 (2.8)
CRP (mg/L)
n	73	40	33	0.907
Median (Q1, Q3)	155 (97.0, 279)	149 (110, 24)	162 (83.0, 386)
Missing (%)	5 (6.4)	2 (4.8)	3 (8.3)
PCT (µg/L)
n	72	37	35	0.0884
Median (Q1, Q3)	1.50 (0.400, 10.9)	0.600 (0.400, 6.00)	4.40 (0.650, 13.8)
Missing (%)	6 (7.7)	5 (11.9)	1 (2.8)
Leucocytes
n	76	41	35	0.26
Median (Q1, Q3)	11.0 (8.43, 14.8)	10.3 (7.30, 14.8)	11.9 (9.45, 14.9)
Missing (%)	2 (2.6)	1 (2.4)	1 (2.8)
Ferritin (ng/mL)
n	48	30	18	0.0418
Median (Q1, Q3)	1260 (894, 2880)	1010 (777, 2000)	1980 (1040, 8140)
Missing (%)	30 (38.5)	12 (28.6)	18 (50.0)
d-Dimer (mg/L)
n	66	38	28	0.364
Median (Q1, Q3)	3.53 (1.07, 25.1)	2.41 (0.848, 24.7)	4.18 (1.51, 23.3)
Missing (%)	12 (15.4)	4 (9.5)	8 (22.2)
Length of ICU stay (days)
n	69	34	35	0.299
Median (Q1, Q3)	17.0 (10.0, 27.0)	15.0 (7.50, 26.3)	19.0 (14.0, 25.5)
Missing (%)	9 (11.5)	8 (19.0)	1 (2.8)
Length of hospital stay (days)
n	78	42	36	0.173
Median (Q1, Q3)	22.0 (15.0, 33.3)	23.5 (16.3, 37.0)	20.0 (13.0, 30.3)
Time from symptoms to Seraph treatment (days)
n	74	39	35	0.0211
Median (Q1, Q3)	12.3 (7.43, 15.5)	9.56 (6.60, 14.6)	13.0 (11.0, 19.5)
Missing (%)	4 (5.1)	3 (7.1)	1 (2.8)
Time from ICU admission to Seraph treatment (days)
n	69	34	35	0.0023
Median (Q1, Q3)	2.55 (1.53, 6.00)	1.73 (1.50, 3.24)	4.58 (2.05, 11.4)
Missing (%)	9^a (11.5)	8 (19.0)	1 (2.8)

ECMO, extracorporeal membrane oxygenation; CRP, C-reactive protein; PCT, procalcitonin.

Non-ICU patients.

This Feature Is Available To Subscribers Only